Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAMNASDAQ:ERASNASDAQ:IMCRNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$17.06-2.2%$17.56$13.53▼$35.25$1.72B2.081.48 million shs1.42 million shsERASErasca$1.48-3.3%$1.34$1.01▼$3.45$419.27M1.091.76 million shs1.46 million shsIMCRImmunocore$34.68-2.7%$31.06$23.15▼$41.54$1.74B0.83362,037 shs435,478 shsTARSTarsus Pharmaceuticals$40.89-0.1%$45.56$20.08▼$57.28$1.72B0.83700,731 shs716,491 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics0.00%-8.18%-1.10%-29.59%-34.54%ERASErasca0.00%-7.50%+16.54%+2.78%-33.33%IMCRImmunocore0.00%-6.90%+19.34%+20.42%-14.43%TARSTarsus Pharmaceuticals0.00%-6.90%-6.00%-14.97%+24.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics3.0661 of 5 stars4.51.00.00.02.22.50.6ERASErasca2.7303 of 5 stars3.50.00.00.03.82.51.3IMCRImmunocore3.0429 of 5 stars4.30.00.00.03.44.20.0TARSTarsus Pharmaceuticals2.1236 of 5 stars3.50.00.00.02.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$48.75185.76% UpsideERASErasca 3.00Buy$4.57208.88% UpsideIMCRImmunocore 2.55Moderate Buy$58.8969.81% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.6763.04% UpsideCurrent Analyst Ratings BreakdownLatest ERAS, BEAM, IMCR, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.006/2/2025TARSTarsus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$75.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/27/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$72.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.005/7/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.005/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.005/2/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $84.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.58M26.98N/AN/A$12.04 per share1.42ERASErascaN/AN/AN/AN/A$2.10 per shareN/AIMCRImmunocore$333.58M5.22N/AN/A$7.42 per share4.67TARSTarsus Pharmaceuticals$233.67M7.35N/AN/A$5.95 per share6.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$132.53M-$4.61N/AN/AN/A-41.07%-16.22%-10.94%8/5/2025 (Estimated)ERASErasca-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)IMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%8/6/2025 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%8/6/2025 (Estimated)Latest ERAS, BEAM, IMCR, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.905.28%N/AN/A N/AERASErascaN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A5.695.69ERASErascaN/A11.0011.00IMCRImmunocore1.033.783.76TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%ERASErasca67.78%IMCRImmunocore84.50%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.50%ERASErasca14.40%IMCRImmunocore10.40%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableERASErasca120283.29 million221.94 millionOptionableIMCRImmunocore32050.23 million45.48 millionOptionableTARSTarsus Pharmaceuticals5042.01 million35.07 millionOptionableERAS, BEAM, IMCR, and TARS HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13 at 3:58 AM | investing.comTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13 at 3:58 AM | investing.comAssenagon Asset Management S.A. Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 12 at 5:58 AM | marketbeat.comE. Ohman J or Asset Management AB Boosts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 7, 2025 | marketbeat.comSquarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 7, 2025 | marketbeat.comStocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS RatingJune 6, 2025 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Time to Sell?June 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 5, 2025 | marketbeat.comWellington Management Group LLP Sells 8,552 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)June 4, 2025 | marketbeat.comTarsus Pharmaceuticals assumed with an Outperform at OppenheimerJune 2, 2025 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by OppenheimerJune 2, 2025 | marketbeat.comNuveen Asset Management LLC Sells 15,186 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 31, 2025 | marketbeat.comQ2 Earnings Forecast for TARS Issued By HC WainwrightMay 30, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Ameriprise Financial Inc.May 30, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by Two Sigma Advisers LPMay 29, 2025 | marketbeat.comTwo Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 29, 2025 | marketbeat.comTarsus Pharmaceuticals' (TARS) Buy Rating Reaffirmed at HC WainwrightMay 28, 2025 | marketbeat.comTarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 27, 2025 | benzinga.comTFG Asset Management GP Ltd Sells 414,117 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 27, 2025 | marketbeat.comToronto Dominion Bank Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERAS, BEAM, IMCR, and TARS Company DescriptionsBeam Therapeutics NASDAQ:BEAM$17.06 -0.38 (-2.18%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$17.18 +0.13 (+0.73%) As of 06/13/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Erasca NASDAQ:ERAS$1.48 -0.05 (-3.27%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.48 +0.01 (+0.34%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Immunocore NASDAQ:IMCR$34.68 -0.95 (-2.67%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$34.63 -0.05 (-0.14%) As of 06/13/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Tarsus Pharmaceuticals NASDAQ:TARS$40.89 -0.06 (-0.15%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$40.88 -0.01 (-0.02%) As of 06/13/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
